GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1260–344.
2.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1211–59.
3.
LakshminarayanKSchisselCAndersonDC, et al.Five-year rehospitalization outcomes in a cohort of patients with acute ischemic stroke: Medicare linkage study. Stroke. 2011;42:1556–62.
4.
DhamoonMSTaiWBoden-AlbalaB, et al.Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke. 2007;38:1752–8.
5.
PolonskiLGasiorMGierlotkaM, et al.A comparison of ST elevation versus non-ST elevation myocardial infarction outcomes in a large registry database: are non-ST myocardial infarctions associated with worse long-term prognoses?Int J Cardiol. 2011;152:70–7.
6.
SerbanMCColantonioLDManthripragadaAD, et al.Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386–95.
7.
HessCNClareRMNeelyML, et al.Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Am Heart J. 2017;187:194–203.
8.
ZhangDSongXChenY, et al.Outcome of patients with prior stroke/transient ischemic attack and acute coronary syndromes. Angiology. 2019;71:324–32.
9.
D’AscenzoFAbu-AssiERaposeiras-RoubinS, et al.Bleemacs: rationale and design of the study. J Cardiovasc Med (Hagerstown). 2016;17:744–9.
10.
DucrocqGAmarencoPLabreucheJ, et al.A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation. 2013;127:730–8.
11.
DucrocqGStegPG. Treating coronary artery disease in patients with a history of cerebrovascular disease. Arch Cardiovasc Dis. 2015;108:606–11.
12.
JamesSKStoreyRFKhurmiNS, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation. 2012;125:2914–21.
13.
WiviottSDBraunwaldEMcCabeCH, et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.
14.
MachFBaigentCCatapanoAL, et al.2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111–88.
